What is Global PNH and aHUS Market?
The Global PNH (Paroxysmal Nocturnal Hemoglobinuria) and aHUS (atypical Hemolytic Uremic Syndrome) Market is a specialized sector within the pharmaceutical industry. PNH and aHUS are rare, life-threatening diseases that affect the blood and small blood vessels of the body. The market for these diseases involves the research, development, and sale of therapeutic treatments. In 2023, the market was valued at a significant US$ 5151.2 million, indicating the high demand and need for effective treatments. The market is expected to grow and reach a value of US$ 7993.1 million by 2030, showing a Compound Annual Growth Rate (CAGR) of 6.4% from 2024 to 2030. This growth is driven by the increasing prevalence of these diseases and the ongoing efforts of pharmaceutical companies to develop new and effective treatments. The United States is currently the largest consumer in this market, accounting for a market share of 52.1% in 2019. This is due to the high incidence of these diseases in the country and the advanced healthcare infrastructure available.
Soliris, Ultomiris in the Global PNH and aHUS Market:
Soliris and Ultomiris are two key drugs in the Global PNH and aHUS Market. Soliris, also known as eculizumab, was the first drug approved for the treatment of PNH and aHUS. It works by inhibiting a part of the body's immune system that can cause damage to red blood cells. Ultomiris, or ravulizumab, is a newer drug that also targets the immune system but has a longer duration of action, meaning it needs to be administered less frequently. Both drugs have been shown to be effective in reducing the symptoms of PNH and aHUS and improving the quality of life for patients. However, they are also associated with high costs, which can be a barrier to access for many patients. The development and success of these drugs have had a significant impact on the Global PNH and aHUS Market, contributing to its growth and shaping its future direction.
PNH, aHUS in the Global PNH and aHUS Market:
The Global PNH and aHUS Market plays a crucial role in the treatment of PNH and aHUS. These diseases can cause a range of symptoms, including fatigue, shortness of breath, and an increased risk of blood clots. Without treatment, they can lead to serious complications such as kidney failure and life-threatening blood clots. The drugs available in this market, such as Soliris and Ultomiris, can help to manage these symptoms and reduce the risk of complications. They work by targeting the underlying cause of the diseases - a malfunctioning immune system - and preventing it from damaging red blood cells. This can help to improve the quality of life for patients and extend their lifespan. However, access to these treatments can be limited by their high cost and the rarity of the diseases, which can make it difficult for patients to get a diagnosis and start treatment.
Global PNH and aHUS Market Outlook:
The future outlook for the Global PNH and aHUS Market is promising, with a projected growth rate of 6.4% from 2024 to 2030. In 2023, the market was valued at US$ 5151.2 million, and it is expected to reach US$ 7993.1 million by 2030. This growth is driven by the increasing prevalence of PNH and aHUS and the ongoing development of new treatments. The United States is currently the largest consumer in this market, with a market share of 52.1% in 2019. This is due to the high incidence of these diseases in the country and the advanced healthcare infrastructure available. However, there is potential for growth in other regions as awareness of these diseases increases and access to treatments improves.
| Report Metric | Details |
| Report Name | PNH and aHUS Market |
| Accounted market size in 2023 | US$ 5151.2 million |
| Forecasted market size in 2030 | US$ 7993.1 million |
| CAGR | 6.4% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
